-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2024-520014-22-00
5
2026-04-22
Locally advanced/metastatic urothelial carcinoma
-
2025-521036-11-00
5
2026-03-23
Immune system disseases
-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2024-512503-39-00
6
2025-12-19
Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
-
2025-522718-22-00
4
2025-12-16
Gastroesophageal Adenocarcinoma
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-519493-39-00
5
2025-12-09
High-risk Non-muscle-invasive Bladder
Cancer with Susceptible FGFR Alt
-
2024-517136-21-00
5
2025-12-05
Renal Cell Carcinoma
-
2025-521059-21-00
4
2025-11-25
Radiographic axial spondyloarthritis (as known as ankylosing spondylit
-
2024-512849-17-00
5
2025-11-14
Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Di
-
2024-519929-38-00
4
2025-10-27
Metastatic Colorectal Cancer without liver metastases
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-520264-33-00
5
2025-10-07
Locoregionally recurrent head and neck squamous cell carcinoma (HNSCC)
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-513682-40-01
5
2025-07-04
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
-
2024-513112-99-00
5
2025-06-13
Active Psoriatic Arthritis Stratified by Prior Biologic Use
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-512302-25-00
5
2025-06-06
Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
-
2024-517335-46-00
4
2025-06-05
Bladder cancer
-
2024-517422-25-00
5
2025-05-22
Metastatic Castration-resistant Prostate Cancer (mCRPC)